A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

Prader-Willi Syndrome Clinical Trial

Official title:

A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05504395
• Other study ID #: CSTI-500-003
• Status: Completed
• Phase: Phase 1
• Start date: November 14, 2022
• Est. completion date: February 21, 2023

Study information

• Verified date: August 2023
• Source: ConSynance Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.

Description:

This is an open-label, single center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in patients with genetically confirmed PWS. The study will consist of a Screening Period of up to 1-3 days prior to the Baseline Visit (Visit 2). In addition to the Screening Visit (Visit 1), eligible subjects will attend five in-clinic site visits for PK blood draws and safety assessments over a 6-day period. At Visit 2 all subjects will receive one single oral dose of CSTI-500 10 mg. Approximately 14 patients aged 13 to 50 years who meet all eligibility criteria will receive one single dose of CSTI-500.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 21, 2023
• Est. primary completion date: February 21, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male and female subjects (13-50 years of age at screening) with a documented medical record history of PWS confirmed by genetic testing.
• Subject must have a reliable caregiver/parent to bring the subject to the site for the visits, remain with the subject during visit times when allowed to be with the subject and respond to any questions during the visits.
• Female subjects must not be pregnant or lactating and be willing to use double barrier birth control method throughout the study.
• A normal supine systolic blood pressure must be =140 mmHg and =100 mmHg; diastolic blood pressure must be =80 mmHg and =60 mmHg at Screening. Pulse rate must be =50 bpm and =100 bpm and pulse rate increase on standing must be within acceptable range.
• All concomitant medications including blood pressure medications and type 2 diabetic medications must be stable for =3 months prior to screening (=10% change). Supplements and vitamins are not considered concomitant medications for eligibility purposes.

Exclusion Criteria:

• Participation in any clinical study with an investigational drug/device within 3 months prior to screening or during the study.
• Recent use (within 3 months) of weight loss agents including prescription, herbal medications, and weight loss supplements.
• Major surgery within 6 months of screening or planned during the study or history of bariatric surgery.
• Any malignancy in the 2 years prior to screening (excluding basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
• Current liver, pulmonary, cardiac, or GI disease that would be expected to adversely affect study participation. Stable disease, e.g., asthma or controlled hypertension is not excluded. Liver disease or liver injury as indicated by abnormal liver function tests, ALT, AST, alkaline phosphatase, or serum bilirubin (=3X ULN for any of these tests).
• Unexplained history or presence of combination of unexplained symptoms e.g., dizziness, syncope, fatigue, palpitations/tachycardia, headaches, or exercise intolerance.
• Heart failure classified per the New York Heart Association (NYHA) level II or greater.
• Myocardial infarction, stroke, or confirmed TIA within the last 5 years.
• Uncontrolled Type 2 diabetes as defined by HbA1c = 9% at Screening.
• Insulin-dependent Type 1 diabetes.
• Subjects with a history of any suicidal behavior.
• Inability to swallow the oral capsule whole with water.

Related Conditions & MeSH terms

• Prader-Willi Syndrome
• Syndrome

Intervention

Drug:
• CSTI-500
Single 10 mg capsule

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
ConSynance Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Concentration (Cmax)	Maximum observed plasma concentration following drug administration determined directly from the concentration-time profile.	Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Primary	AUC0-72	Area under the plasma-drug concentration-time curve from pre-dose (time 0) to 72 hours after drug administration	Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose
Primary	AUC0-inf	Area under the plasma-drug concentration-time curve from pre-dose (time 0) extrapolated to infinite time	Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Primary	CSTI-500 plasma concentration		1 hour post-dose
Primary	CSTI-500 plasma concentration		2 hour post-dose
Primary	CSTI-500 plasma concentration		4 hour post-dose
Primary	CSTI-500 plasma concentration		8 hour post-dose
Primary	CSTI-500 plasma concentration		12 hour post-dose
Primary	CSTI-500 plasma concentration		24 hour post-dose
Primary	CSTI-500 plasma concentration		48 hour post-dose
Primary	CSTI-500 plasma concentration		72 hour post-dose
Primary	CSTI-500 plasma concentration		144 hour post-dose
Secondary	Incidence of treatment-emergent adverse events (TEAEs)	Number of participants with TEAEs, defined as an adverse event (AE) that is new or worsened in severity after the dose of study drug. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized by system organ class, preferred term, and treatment.	From pre-dose to 15 days post-dose
Secondary	Incidence of clinically significant findings in physical examinations		Screening to 12, 24, 48, 72, and 144 hours post-dose
Secondary	Incidence of clinically significant findings in vital signs	Participants will be assessed for any clinically significant changes in vital parameters (blood pressure, heart rate in supine and standing position, respiratory rate, and body temperature). This also includes evaluation of postural orthostatic tachycardic syndrome.	Screening and pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Secondary	Incidence of clinically significant findings in laboratory values	Laboratory evaluations include hematology, thyroid function, and chemistry blood and urine laboratory tests.	Screening to 24, 48, 72, and 144 hours post-dose
Secondary	Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)		Screening and pre-dose to 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Secondary	Comparison of CSTI-500 Cmax values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects		Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Secondary	Comparison of CSTI-500 AUC0-72 values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects		Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose
Secondary	Comparison of CSTI-500 AUC0-inf values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects		Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose